

RAPID DOSE THERAPEUTICS CORP.
(formerly ACME Resources Corp.)

NOTICE OF CHANGE IN CORPORATE STRUCTURE
Pursuant to Section 4.9 of
National Instrument 51-102 – *Continuous Disclosure Obligations*

December 18, 2018

Delivered via SEDAR

TO: Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission
(collectively, the “**Jurisdictions**”)

Re: RAPID DOSE THERAPEUTICS CORP. (formerly, ACME Resources Corp.)
(the “Issuer” or the “Corporation”)

Pursuant to Section 4.9 of National Instrument 51-102 *Continuous Disclosure Obligations*, the Issuer hereby confirms the following:

1. Names of the Parties to the Transaction

Rapid Dose Therapeutics Corp. (formerly, ACME Resources Corp.) (the “**Issuer**” or the “**Corporation**”)
1163926 B.C. Ltd. (“**Subco**”)
Rapid Dose Therapeutics Inc. (“**RDT**”)

2. Description of the Transaction

On December 7, 2018, the Issuer completed a three-cornered amalgamation of its wholly-owned subsidiary, Subco, with RDT (the “**Amalgamation**”) pursuant to an Amended and Restated Amalgamation Agreement (the “**Amalgamation Agreement**”) dated July 11, 2018 as further amended (the “**Transaction**”).

Pursuant to the terms of the Transaction, the Issuer acquired 100% of the issued and outstanding common shares of RDT (the “**RDT Shares**”) by the issuance of approximately 64,841,200 Common Shares of the Corporation (the “**Common Shares**”), 4,907,937 Common Shares to an arm’s length party in payment of corporate finance services fees, and 840,000 warrants (the “**Issuer Warrants**”) with each Issuer Warrant issued on substantially identical terms to the outstanding warrants in the capital of RDT (the “**RDT Warrants**”) to replace each automatically cancelled RDT Warrant.

On closing of the Amalgamation, the Corporation issued, and each holder of RDT Shares received, one Common Share in exchange for each RDT Share held immediately prior to the Amalgamation and the Corporation issued, and each holder of the RDT Warrants received, one Issuer Warrant in exchange for each RDT Warrant held immediately prior to the Amalgamation, each such Issuer Warrant having identical terms to the RDT Warrants in respect of exercise price, expiry date and all other material terms and conditions.

Upon completion of the Amalgamation and the issuance of the Common Shares to the arm length's party, the Corporation has 75,021,327 Common Shares issued and outstanding of which approximately 7% are held by the original shareholders of the Issuer, and approximately 86% are held by the former RDT shareholders. The Corporation also has 840,000 Issuer Warrants outstanding.

As a part of the Transaction, on December 10, 2018 the Issuer changed its name from ACME Resources Corp. to Rapid Dose Therapeutics Corp.

3. The Effective Date of the Transaction

The Transaction was completed effective December 7, 2018.

4. Name of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity

Rapid Dose Therapeutics Corp. (formerly ACME Resources Corp.) continues to be a reporting issuer in each of the Jurisdictions.

5. Date of First Financial Year-End

The Corporation changed its financial year to adopt RDT's year end of February 28. The date of the first financial year end following closing of the Transaction is February 28, 2019.

6. Interim and Annual Financial Statements Required to Be Filed

The Issuer's first annual financial statements required to be filed after the Transaction are for the year ended September 30, 2018 with comparative statements for the year ended September 30, 2017. The Issuer's transitional year financial statements on a consolidated basis required to be filed after the Transaction will be for the year ending February 28, 2019.

The first interim financial statements required to be filed after the Transaction are RDT's interim financial statements for the nine months ended November 30, 2018 followed by the Issuer's regular consolidated interim financial statements to be filed

for the interim periods ending May 31, August 31 and November 30 in each subsequent year.

7. Documents Filed

For additional information relating to the above-noted Transaction, please refer to the following documents filed on SEDAR and available at www.sedar.com under the company site for the Issuer:

- (a) a news release disseminated on July 12, 2018 announcing the entering into the Amalgamation Agreement - filed on SEDAR on July 12, 2018;
- (b) Amalgamation Agreement - filed on SEDAR on July 12, 2018;
- (c) material change report with respect to the Amalgamation Agreement - filed on SEDAR on July 12, 2018;
- (d) preliminary long-form prospectus dated July 12, 2018 together with preliminary receipt – filed on SEDAR on July 13, 2018;
- (e) notice of special meeting, management information circular, letter of transmittal and proxy-related materials with respect to the special meeting of shareholders of the Issuer - filed on SEDAR on August 9, 2018;
- (f) news release disseminated on September 5, 2018 announcing the shareholder approval of the Amalgamation - filed on SEDAR on September 5, 2018;
- (g) final long-form prospectus dated December 5, 2018 together with final receipt – filed on SEDAR on December 6, 2018;
- (h) news release announcing the filing of final long-form prospectus – filed on SEDAR on December 6, 2018;
- (i) news release announcing the completion of the Transaction - filed on SEDAR on December 7, 2018;
- (j) Articles of Amendment - filed on SEDAR on December 10, 2018;
- (k) news release announcing change of name of the Issuer and its management – filed on SEDAR on December 10, 2018;
- (l) material change report with respect to the filing of the long-form prospectus, completion of the Amalgamation, change of name of the Issuer and its management - filed on SEDAR on December 14, 2018; and
- (m) CSE Form 2A – *Listing Statement* dated December 12, 2018 - filed on SEDAR on December 14, 2018.